Lexicon Pharma (LXRX) Tops Q2 EPS by 11c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.15 +6.97%
Revenue Growth %: -86.1%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -86.1%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.33), $0.11 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $12.1 million versus the consensus estimate of $18.34 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
- AeroVironment restates quarterly financials, citing $89M goodwill error
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
